Pfizer's Q2 2026 revenue topped market expectations at $15.034 billion. According to the company's SEC 8-K filing, it also raised its full-year revenue guidance.
Earnings at a Glance
Pfizer's Q2 2026 revenue came in at $15.034 billion, up 3% year-over-year. Growth excluding currency effects was 1%. Excluding COVID-19 vaccine and treatment products (Comirnaty and Paxlovid), revenue grew 5%. Recently launched or acquired drugs drove growth, with sales up 18%. However, a $4.3 billion intangible asset impairment charge pushed the company to a net loss on a GAAP basis.
- Revenue: $15.034 billion, up 3% year-over-year (up 1% excluding currency effects)
- Earnings per share (EPS): Adjusted EPS of $0.77, roughly in line with $0.78 a year earlier; GAAP EPS was a loss of $0.04 per share
- GAAP net loss: $248 million, driven by a $4.3 billion asset impairment charge
- Adjusted net income: $4.44 billion, nearly flat versus $4.434 billion a year earlier
Full-Year Guidance
Pfizer raised its full-year 2026 revenue guidance to $60.5 billion-$62.5 billion. That's up $500 million at the midpoint from its previous guidance of $59.5 billion-$62.5 billion. The company lowered its outlook for COVID-19 vaccine and treatment sales to $4.0 billion, down from $5.0 billion previously. Meanwhile, it expects sales of other drugs to come in $1.5 billion stronger than previously anticipated. Adjusted EPS guidance was kept unchanged at $2.80-$3.00, reflecting a roughly $0.10 hit from a $650 million licensing deal cost with Innovent Biologics that will be recorded in Q3. Incoming interim CFO Cecile Guegan said the quarter's results reflect strong commercial performance across global markets and continued cost-efficiency efforts. Pfizer also unveiled plans for an additional $2.5 billion in cost cuts through 2027-2029.
Market Reaction
CNBC and The Wall Street Journal reported that Pfizer beat market expectations on strong sales of cardiovascular drugs including Eliquis and its oncology portfolio. Morningstar noted that growth from newer drugs offset declining COVID-19 product sales. BioPharma Dive, Fierce Pharma, and BioSpace reported on Pfizer's plan for an additional $2.5 billion in cost cuts through 2029. The stock's price movement immediately following the announcement was not disclosed.
By Business Segment
- Global Biopharmaceuticals segment: $14.661 billion, up 2% year-over-year (up 1% excluding currency effects)
- Pfizer CentreOne (contract manufacturing segment): $373 million, up 7% year-over-year (up 5% excluding currency effects)
This article was automatically generated based on the original SEC 8-K filing and news wire reports, with the goal of delivering key data promptly after the announcement. Readers are advised to review the company's official filing before making trading decisions. Prices reflect the time this article was written and may differ from current levels.
